# Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma

> **NCT01765231** · PHASE4 · UNKNOWN · sponsor: **Peking University** · enrollment: 190 (estimated)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Entecavir prophylaxis
- **DRUG:** Observation arm

## Key facts

- **NCT ID:** NCT01765231
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2017-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01765231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01765231, "Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01765231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*